Why Is OmniAb (OABI) Stock Up +21.01% Today?
Key Takeaways
- OABI shares jumped 21.01% to $4.09 in mid-morning trading Monday, up from Friday’s close of $3.38.
- The primary catalyst was a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program.
- OmniAb is eligible for up to $370 million in development and commercial milestones, plus tiered royalties; the upfront payment was not disclosed.
- The company also raised its 2026 cash outlook to $49 million–$53 million, up from $37 million–$41 million.
- The move was stock-specific: broader equity index futures were roughly flat at the time of the rally.
- Traders are watching whether the stock can hold above its prior 52-week high of $3.63 after an extended run.
Opening Summary
OmniAb, Inc. (OABI), a biotechnology company that licenses antibody and ion channel discovery technology to pharmaceutical, biotech, and academic partners, saw its stock surge 21.01% on Monday. As of 9:40 a.m. ET, shares traded at $4.09, compared with the previous completed session’s closing price of $3.38. The move extended a rally that began earlier this month after strong second-quarter results, with Monday’s advance driven by a new collaboration with Eli Lilly and Company (LLY) and an increase in OmniAb’s full-year cash guidance.
Eli Lilly Collaboration and License Agreement
The main driver of Monday’s share-price surge was OmniAb’s announcement of a global collaboration and license agreement with Eli Lilly for a new ion channel program. Under the agreement, Lilly will use OmniAb’s ion channel discovery and screening capabilities. OmniAb will receive an upfront payment of undisclosed size and is eligible for up to $370 million in research, development, and commercial milestone payments, along with tiered royalties on global net sales. The companies did not disclose the therapeutic target or modality.
The deal matters because it pairs OmniAb’s platform with one of the world’s largest pharmaceutical companies and validates the company’s ion channel capabilities beyond its established antibody discovery franchise. For a small-cap biotechnology name, the milestone and royalty economics signal potential long-term, non-dilutive cash flow if the partnered program advances.
Raised 2026 Cash Guidance
Alongside the Lilly announcement, OmniAb raised its 2026 cash outlook following recent technology licensing activity. The company now expects to end the year with $49 million to $53 million in cash and cash equivalents, up from its previous forecast of $37 million to $41 million. Management cited strengthening business development and licensing activity, which reinforced the market’s view that the company’s platform is gaining broader commercial traction.
Earnings Momentum and Technical Breakout
Monday’s rally also reflects continued momentum from OmniAb’s second-quarter results, released earlier in August. The company reported revenue of about $13.4 million, up sharply from roughly $3.9 million in the prior-year period, while its net loss narrowed. Management raised full-year 2026 revenue guidance to $32 million–$36 million, above its previous range of $28 million–$33 million, as milestone revenue from advancing partner programs increased.
The stock has been in a powerful uptrend since the earnings-driven move, climbing from around $2 in early August to a new 52-week high above $3.63. Monday’s gap higher pushed shares well beyond that level. Momentum indicators have become extended, however, with relative strength readings in overbought territory, leaving the stock vulnerable to sharp profit-taking after its rapid advance.
Market Context and Trading Activity
Trading activity was unusually heavy. More than 1.1 million shares changed hands in the first ten minutes of the regular session, already surpassing Friday’s entire full-session volume of roughly 329,000 shares. Shares opened at $4.18, touched an early high of $4.20, and then settled near $4.09 in mid-morning trading.
The advance was largely company-specific. Broader equity index futures were close to flat, indicating that the deal announcement, rather than sector-wide or macro sentiment, drove the move. OmniAb’s sharp gap higher broke decisively above its prior 52-week high, a technical level that had served as resistance, but the extended positioning leaves the stock susceptible to volatility if early gains are not sustained.
What Comes Next for OABI
Investors will now look for additional details on the Lilly collaboration, including the size of the upfront payment and the timeline for milestone opportunities. OmniAb’s business remains dependent on partner decisions, and milestone revenue can be lumpy from quarter to quarter. The raised cash guidance reduces near-term balance-sheet concerns, but the company is still unprofitable, and its valuation has expanded rapidly. Key upcoming catalysts include further licensing announcements, partner program progress, and OmniAb’s next quarterly earnings update. Risks include profit-taking after the extended run, broader biotechnology-sector sentiment, and the inherent uncertainty of partnered drug development programs.
Trending AI Robots
Tickeron’s Trending AI Robots page offers a curated view of AI-powered trading bots that are currently among the strongest performers under prevailing market conditions. Tickeron provides hundreds of AI trading bots covering thousands of tickers, with strategies, timeframes, performance metrics, and traded symbols varying across the platform. Traders and investors can use the page to monitor which algorithmic approaches are adapting best to today’s markets. Explore the Trending AI Robots section to see which systems are attracting attention right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
OABI in -6.84% downward trend, falling for three consecutive days on September 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OABI declined for three days, in 205 of 245 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for OABI moved out of overbought territory on September 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 26 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OABI as a result. In 64 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for OABI turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 34 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 63 cases where OABI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +2.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where OABI advanced for three days, in 143 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 79 of 177 cases where OABI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.497) is normal, around the industry mean (25.929). P/E Ratio (0.000) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (14.124) is also within normal values, averaging (437.043).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OABI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OABI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement